Latest Amedisys Inc (AMED) Headlines Amedisys R
Post# of 31
Amedisys Reports Fourth Quarter Financial Results
Business Wire - Wed Mar 12, 6:00AM CDT
Amedisys, Inc. (NASDAQ: AMED), a leading home health and hospice company, today reported its financial results for the fourth quarter and year ended December 31, 2013.
Downgrade Alert for Amedisys (AMED)
Comtex SmarTrend(R) - Tue Mar 11, 7:07AM CDT
Amedisys (NASDAQ:AMED) was downgraded from Outperform to Perform at Oppenheimer today. The stock closed yesterday at $16.20 on volume of 205,000 shares, below average daily volume of 244,000. Based on a current price of $16.20, Amedisys is currently 35.6% above its average consensus analyst price target of $10.43. The stock should discover initial support at its 50-day moving average (MA) of $15.51 and subsequent support at its 200-day MA of $15.12.
Amedisys Announces Fourth Quarter Earnings Release and Conference Call Date
Business Wire - Wed Mar 05, 10:00AM CST
Amedisys, Inc. (NASDAQ: AMED), one of America's leading home health and hospice care companies, announced today that it will host a conference call to discuss results for the fourth quarter ended on December 31, 2013 on Wednesday, March 12, 2014 at 10:00 a.m. Eastern Time (9:00 a.m. Central Time). The Company will issue its quarterly earnings release prior to hosting the conference call.
Amedisys Chairman & CEO William Borne Steps Down
Business Wire - Mon Feb 24, 7:31AM CST
Amedisys, Inc. (NASDAQ: AMED), one of America's leading home health and hospice care companies, today announced that William (Bill) F. Borne, Chief Executive Officer and Chairman of the Board, has stepped down as CEO, Chairman and Director. In recognition of his 33 years of service since founding the Company in 1982, the Board of Directors has named Mr. Borne Chairman Emeritus.
EMC Insurance Group Inc. Reports 2013 Fourth Quarter and Year-End Results and 2014 Operating Income Guidance
Business Wire - Thu Feb 20, 5:30AM CST
--Year Ended December 31, 2013Operating Income Per Share - $2.88Net Income Per Share - $3.33Net Realized Investment Gains Per Share - $0.45Catastrophe and Storm Losses Per Share - $2.41Large Losses Per Share - $1.10GAAP Combined Ratio - 97.9 percent
Increasing Health Care at Home Integral to Success of the Affordable Care Act
Business Wire - Wed Jan 22, 10:53AM CST
If the Affordable Care Act (ACA) is to deliver on its promises, especially in properly coordinating care for the fast-growing population of chronically ill Americans, then delivering health care right to our own homes is increasingly essential.
Commit To Purchase Amedisys At $10, Earn 7.7% Using Options
StockOptionsChannel.com - Thu Jan 16, 10:38AM CST
Investors eyeing a purchase of Amedisys, Inc. shares, but cautious about paying the going market price of $15.63/share, might benefit from considering selling puts among the alternative strategies at their disposal.
A Tribute to Gabrielle Giffords and Rehab Therapists Everywhere
Business Wire - Mon Jan 13, 12:18PM CST
A long-time physical therapist at Amedisys recently paid heartfelt tribute to Gabrielle Giffords, the courageous Congresswoman and advocate for gun control reform still recovering from a gunshot wound three years ago - and also, more broadly, honored the unsung miracle workers known as rehabilitation specialists.
Amedisys to Present at the 32nd Annual J.P. Morgan Healthcare Conference
Business Wire - Thu Jan 09, 10:59AM CST
Amedisys, Inc. (NASDAQ: AMED), one of America's leading home health and hospice care companies, today announced that William F. Borne, Chief Executive Officer, will present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 15, 2014.
Financial Results, Conference Presentation Schedule, Clinical Trial Initiation, Recognition, and Dividend Payment - Research Report on Cantel, Chimerix, Verastem, Amedisys, and Ensign Group
PR Newswire - Wed Dec 25, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
2013 HomeCare Elite Recognizes Top Amedisys Care Teams Nationwide
Business Wire - Wed Dec 18, 1:53PM CST
Amedisys, a leading healthcare at home company (NASDAQ: AMED), today announced that 155 of its care centers across the country have been named to the 2013 HomeCare Elite(TM), a compilation of the top-performing home health agencies in the United States compiled annually by OCS Home Care and DecisionHealth. Now in its eighth year, the HomeCare Elite identifies the top 25 percent of agencies and further highlights the top 100 and top 500 agencies overall. Winners are ranked by an analysis of publicly available performance measures in quality outcomes, best practice (process measure) implementation, patient experience (Home Health CAHPS(R)), quality improvement and consistency, and financial performance.
2013 Report on the North American Home Healthcare Market - Includes Forecasts To 2017
M2 - Tue Dec 17, 5:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/6zxkbc/north_american) has announced the addition of the "2013 Report on the North American Home Healthcare Market - Includes Forecasts To 2017" report to their offering. While the United States dominated the market last year, Canada is expected to grow steadily due to increasing awareness regarding home based devices, and increasing prevalence of lifestyle diseases such as diabetes, obesity, and cardiovascular diseases and various initiatives taken by government to promote home healthcare. The prominent home healthcare service provider companies are Apria Healthcare Group (U.S.), Gentiva Health Service Inc. (U.S.) and Amdisys, Inc. (U.S.) while key home healthcare product manufacturing companies are Alere, Inc. (U.S.), Baxter International, Inc. (U.S.), B. Braun Melsungen AG (Germany), Fresenius Se & Co KGAa (Germany), GE Healthcare (U.K), Philips Healthcare (The Netherlands), and Roche Holdings (Switzerland). Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Home Healthcare Testing, Screening & Monitoring Market 5 Home Healthcare Therapeutic Equipment 6 Mobility Assist & Other Devices 7 Nutrition 8 Fitness Market 8.1 Introduction 8.2 Heart Rate Monitors 8.3 Cardiovascular Exercise Equipments 8.4 Body Composition Analyzers 9 Home Healthcare Services Market 9.1 Introduction 9.2 Rehabilitation Therapy Services 9.3 Unskilled Care 9.4 Infusion Therapy 9.5 Respiratory Therapy 10 Home Telehealth Market 10.1 Introduction 10.2 Home Telehealth Monitoring Devices 10.3 Home Telehealth Services 11 Geographic Analysis 11.1 Introduction 11.2 U.S. 11.3 Canada 12 Competitive Landscape 12.1 Introduction 12.2 Mergers & Acquisitions 12.3 Agreements, Partnerships, Collaborations & Joint Ventures 180 12.4 New Product Developments 12.5 Others 12.6 FDA Approvals 13 Company Profiles Companies Mentioned: - Alere, Inc - Amedisys, Inc - Apria Healthcare Group, Inc - B Braun Melsungen AG - Baxter International, Inc - Fresenius Se & Co KGAA - GE Healthcare (Subsidiary Of General Electric Company) - Gentiva Health Services, Inc - Philips Healthcare (Subsidiary Of Royal Philips Electronics) - Roche Holding AG For more information visit http://www.researchandmarkets.com/research/6z...h_american
New Clinical Trials, Pricing of Common Stock and Adjusted Conversion of Convertible Senior Notes - Research Report on Regeneron, Celldex, PDL BioPharma, Amedisys, and Exelixis
PR Newswire - Wed Dec 11, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
Amedisys and HomecareCRM Bring Customer Relationship Management To New Levels of Performance
Business Wire - Mon Dec 09, 9:24AM CST
Amedisys, Inc., one of America's leading healthcare-at-home companies, has reaffirmed a continuing relationship with HomecareCRM, recognizing the positive impact of HomecareCRM's customer relationship management solution. Amedisys delivers personalized home health and hospice care to more than 360,000 patients each year, and more than 2,200 hospitals and 61,900 physicians nationwide have chosen Amedisys as a partner in post-acute care.
Amedisys to Present at the 24th Annual Oppenheimer Healthcare Conference
Business Wire - Thu Dec 05, 1:00PM CST
Amedisys, Inc. (NASDAQ: AMED), one of America's leading home health and hospice care companies, today announced that Thomas J. Dolan, Senior Vice President of Finance and Treasurer, will present at the 24th Annual Oppenheimer Healthcare Conference in New York, NY on Wednesday, December 11, 2013.
Upgrade Alert for Amedisys (AMED)
Comtex SmarTrend(R) - Tue Nov 26, 7:08AM CST
Amedisys (NASDAQ:AMED) was upgraded from Market Perform to Outperform at Avondale today. The stock closed yesterday at $15.92 on volume of 830,000 shares, above average daily volume of 641,000. Amedisys (NASDAQ:AMED) is currently priced 34.4% above its average consensus analyst price target of $10.44. Amedisys shares should encounter resistance at the 50-day moving average (MA) of $16.74 and support at its 200-day MA of $13.62.
Settlement Agreement, Presentation of Trial Results, and Stock Price Update - Research Report on Johnson & Johnson, Mettler-Toledo, Galena Biopharma, Dendreon, and Amedisys
PR Newswire - Mon Nov 25, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Johnson & Johnson (NYSE: JNJ), Mettler-Toledo International, Inc. (NYSE: MTD), Galena Biopharma, Inc. (NASDAQ: GALE), Dendreon Corp. (NASDAQ: DNDN), and Amedisys Inc. (NASDAQ: AMED). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Amedisys Webinars to Educate Physicians about Home Health and Hospice
Business Wire - Fri Nov 22, 4:01PM CST
In recognition of National Home Care and Hospice Month - and also in response to growing public demand - Amedisys and Antidote Education Company have teamed up again to offer Continuing Education webinars for physicians on two increasingly important topics: home health and hospice care.
Financial Results, New Products, and Stock Price Movements - Research Report on Hologic, Johnson & Johnson, Boston Scientific, Elan, and Amedisys
PR Newswire - Fri Nov 15, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Hologic, Inc. (NASDAQ: HOLX), Johnson & Johnson (NYSE: JNJ), Boston Scientific Corporation (NYSE: BSX), Elan Corporation, plc (ADR) (NYSE: ELN), and Amedisys Inc. (NASDAQ: AMED). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Amedisys slump deepens on settlement, new guidance
AP - Wed Nov 13, 1:11PM CST
NEW YORK (AP) — Shares of Amedisys extended their decline Wednesday after the home health company said it will pay $150 million to settle a federal investigation and reported weak third-quarter results.